Mar 012018
 March 1, 2018  Posted by  Featured News, Healthcare

Ben Hirschler reports:

Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world.

Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs – something Roche (ROG.S) aims to leverage, for example, with last month’s $2 billion purchase of Flatiron Health.

Read more on Reuters.

Sorry, the comment form is closed at this time.